Vivo Capital, a global healthcare investment firm, announced the closing of a new healthcare venture capital focused fund, the Vivo PANDA Fund (“Vivo PANDA”), at over $100 million.
Vivo plans to invest the capital primarily in innovative early-stage healthcare companies across the industry spectrum, including pharmaceuticals, biotechnology, medical devices, and diagnostics. The addition of Vivo PANDA will enable the firm to invest in all stages in the life science industry’s development cycles. Vivo PANDA will complement and build synergies with Vivo Capital Fund VIII, which invests primarily in later development stage and growth stage healthcare companies.
Vivo also intends to continue its strategy of collaborating with portfolio companies on both sides of the Pacific in their efforts to forge cross-border partnerships. Through its bridge strategy, Vivo intends to promote cross-border dialogue and collaboration, enabling companies to accelerate innovation, acquire new products, and expand the market for their existing products.
Investors in Vivo PANDA include financial institutions, corporate entities, and family offices.
In addition to the close of the fund, the firm also announced the opening of its office in Taipei, Taiwan. The firm’s new Taipei office is located at 18/F, No. 460, Section 4, Xinyi Road, Xinyi District, Taipei, Taiwan.
About Vivo Capital
Founded in 1996, Vivo Capital is a global healthcare investment firm focused on investing in and building high quality companies. With more than $1.8 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising technologies. Vivo Capital (http://www.vivocapital.com/) has offices in Palo Alto, Beijing, Shanghai, and Taipei.